Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q4 EPS of ($0.81), $0.22 better than the analyst estimate of ($1.03).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
• A.O. Smith executive chairman to retire, CEO to assume chairman role